Further studies need to be undertaken in order to investigate whether the expression of heparanase isoforms and higher levels of enzymatic activity of heparanase-1 and cathepsin B in the plasma can be used to improve the diagnosis and also as potential novel therapeutic targets in cases of gastrointestinal carcinoma. Here, CTSB is linked to digestive system carcinoma.